Leerink Partnrs Has Positive Outlook for Zoetis Q3 Earnings

Zoetis Inc. (NYSE:ZTS) – Research analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for Zoetis in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $1.68 for the quarter, up from their prior forecast of $1.64. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.22 EPS, FY2026 earnings at $6.88 EPS, FY2027 earnings at $7.48 EPS and FY2028 earnings at $8.07 EPS.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 earnings per share.

A number of other brokerages also recently commented on ZTS. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $212.13.

Zoetis Price Performance

Shares of ZTS opened at $159.96 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $71.37 billion, a PE ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. The company has a 50 day moving average price of $157.27 and a 200-day moving average price of $166.06. Zoetis has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Institutional Investors Weigh In On Zoetis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. lifted its stake in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC purchased a new position in shares of Zoetis during the fourth quarter worth $30,000. Cornerstone Planning Group LLC grew its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock valued at $42,000 after buying an additional 120 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.